文献速递产科母胎医学

妊娠期选择性5-羟色胺再摄取抑制剂使用轨迹与围产结局:一项纵向登记研究

Trajectories of Selective Serotonin Reuptake Inhibitor Use in Pregnancy and Perinatal Outcomes: A Longitudinal Register Study.
PubMed 文献 · BJOG · 2025-08-20

该纵向登记研究纳入553名孕期报告使用SSRI的产妇,并按抑郁、精神科诊断和年龄匹配五倍对照组(n=2765),采用无监督k-Means纵向聚类识别四种SSRI使用模式,以未暴露组为参照分析其与围产结局的关联。结果显示,至标准剂量的SSRI使用与围产结局无关联,但持续高剂量组(约为标准剂量两倍)胎盘重量和胎盘-出生体重比更高,NICU入住风险为未暴露组的2倍(95%CI=1.05,3.76),平均SSRI剂量与胎盘重量、PBWR和脐带长度呈线性关联。

要点

  • 至标准剂量的SSRI使用与围产结局无关联。
  • 持续高剂量组胎盘重量和PBWR高于未暴露组。
  • 持续高剂量组NICU入住风险为未暴露组2倍。

核心结论

  • 至标准剂量的SSRI使用与不良围产结局无关联,但线性剂量-反应关联和持续较高剂量提示胎盘效能可能降低及不良围产健康风险增加,需谨慎。

研究设计与样本

  • 纵向登记研究,来自Kuopio大学医院出生登记。
  • 553名孕期报告使用SSRI的产妇按抑郁、精神科诊断和年龄匹配五倍对照组(n=2765)。
  • 采用无监督k-Means纵向聚类识别四种SSRI使用模式,并以广义估计方程进行倾向评分调整回归分析,以未暴露组为参照。

主要发现

  • 与未使用SSRI组相比,至标准剂量的SSRI使用与围产结局无关联。
  • 持续高剂量组(约为标准剂量两倍)胎盘重量较高(B=36.9,95%CI=3.2,70.7),PBWR较高(B=1.54,95%CI=0.70,2.38),NICU入住风险为未使用SSRI组的2倍(95%CI=1.05,3.76)。
  • 平均SSRI剂量与胎盘重量、PBWR和脐带长度呈线性关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We examined the possible impact of selective serotonin reuptake inhibitor (SSRI)-trajectories describing the timing of different SSRI dosages on adverse perinatal outcomes. DESIGN: Longitudinal register study. SETTING: Study from Kuopio University Hospital Birth Register. POPULATION OR SAMPLE: Altogether 553 mothers who reported using SSRIs in pregnancy were matched to a five-fold comparison group (n = 2765), based on depression, psychiatric diagnoses and age. METHODS: We applied unsupervised k-Means longitudinal clustering to identify four distinct patterns of SSRI use, and propensity score adjusted regression models based on generalised estimating equations to examine the associations between the exposure groups and the perinatal outcomes, using the unexposed group as reference. Secondary analyses assessed linear associations between average SSRI dose and outcomes. MAIN OUTCOME MEASURES: Birth weight, placental weight, placental-to-birth-weight ratio (PBWR), umbilical cord length, gestational length, preterm birth (< 37 gestational weeks), low 5-min Apgar score, neonatal intensive care unit (NICU) admission. RESULTS: Compared to the no SSRI group, we found no associations between the use of SSRI up to standard doses and the perinatal outcomes. However, the sustained high dose group (~twice the standard dose) displayed higher placental weight (B = 36.9, 95% CI = 3.2, 70.7) and PBWR (B = 1.54, 95% CI = 0.70, 2.38), and the risk of NICU admission was 2-fold (95% CI = 1.05, 3.76), compared with the no SSRI group. The average SSRI dose was linearly associated with placental weight, PBWR, and umbilical cord length. CONCLUSIONS: SSRI use up to standard doses was not associated with adverse perinatal outcomes. However, linear dose-response associations and sustained higher doses suggest potentially reduced placental efficacy and increased risk of adverse perinatal health, warranting caution.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Bernhardsen GP, Pesonen M, Keski-Nisula L, et al. Trajectories of Selective Serotonin Reuptake Inhibitor Use in Pregnancy and Perinatal Outcomes: A Longitudinal Register Study. BJOG. 2025. PMID: 40836389. doi:10.1111/1471-0528.18337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。